{
  "meta": {
    "title": "Cystic fibrosis",
    "url": "https://brainandscalpel.vercel.app/cystic-fibrosis-03ce1adf-fb1254.html",
    "scrapedAt": "2025-12-01T05:58:46.788Z",
    "type": "article"
  },
  "content": "\n                <div><h1>Introduction</h1>\n<p>Cystic fibrosis (CF) involves production of abnormally thick epithelial mucus leading to progressive scarring and dysfunction across multiple organs, particularly in the lungs, pancreas, liver, and reproductive systems.&nbsp; It is the most common monogenic disorder, affecting ~1/3,000 live births, with ~1/25 Caucasian adults being carriers.</p>\n<h1>Pathogenesis</h1><h2>Genetics and molecular biology</h2><br><br><p>CF is an autosomal recessive disorder due to inheritance of 2 abnormal copies of the <strong>cystic fibrosis transmembrane conductance regulator (</strong><em><strong>CFTR</strong></em><strong>)</strong> gene.&nbsp; Mutations in <em>CFTR</em> result in a protein that is truncated (eg, G542X), is nonfunctional (eg, G551D), or fails to reach the cell surface (Î”F508).&nbsp; <strong>Î”F508</strong> is the most common mutation, accounting for ~70% of CF cases.&nbsp; Î”F508 (ie, deletion of phenylalanine at position 508) leads to misfolding and subsequent proteasomal degradation of the CFTR protein (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L16555.jpg\" alt=\"figure 1\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 1</div>\n                                </div>\n                                ).&nbsp; Approximately 2,000 mutations of CFTR have been discovered, but only a minority are clinically consequential (ie, variable penetrance).&nbsp; Compound heterozygosity with 2 alleles can also produce significant CF clinical disease (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L69539.jpg\" alt=\"figure 2\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 2</div>\n                                </div>\n                                ).&nbsp; The CFTR protein is an apical (ie, lumen-facing) <strong>epithelial chloride channel</strong> that actively (ie, using ATP) transports chloride out of the cell.&nbsp; Movement of chloride creates an electrochemical potential that also draws sodium and water across the cell membrane, promoting hydration and thinning of mucus secretions.&nbsp; The impact of CFTR <strong>depends on orientation</strong> of the channel, which is different at different sites (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L28038.jpg\" alt=\"figure 3\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 3</div>\n                                </div>\n                                ):<p></p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Mucosae:&nbsp; CFTR is oriented outward, functioning to excrete chloride (as well as sodium, bicarbonate, and water) into the lumen.&nbsp; Abnormal CFTR function results in desiccated, thick mucus that clogs organ lumens (eg, airways, pancreaticobiliary ducts), leading to clinical manifestations of recurrent pneumonias and pancreatic failure.</li>\n\t<li>Eccrine sweat glands:&nbsp; CFTR is oriented inward, functioning to remove chloride from the sweat (creates hypotonic sweat relative to plasma).&nbsp; Abnormal CFTR function results in hypertonic sweat with elevated chloride and sodium (eg, salty).&nbsp; This forms the basis of the ionophoric <strong>sweat chloride test</strong>.</li>\n</ul>\n<h2>Bronchiectasis</h2><br><br><p>Cilia are an insufficient defense against the viscous (\"sticky\") CF mucus.&nbsp; Mucostasis in the sinuses and airways leads to bacterial trapping, colonization, overgrowth, chronic infection, and recurrent bouts of sinusitis and bronchopneumonia.&nbsp; Cycles of neutrophilic inflammation and bacterial infection lead to bronchiectasis (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L30083.jpg\" alt=\"figure 4\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 4</div>\n                                </div>\n                                ), with the bronchial walls progressively and irreversibly damaged and weakened.&nbsp; This results in dilated, tubular, mucus-filled airways with increased collapsibility, leading to further obstruction and mucus retention.<p></p><br><br><p>Bacterial microbiology in CF-related bronchiectasis changes with age (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L66536.png\" alt=\"figure 5\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 5</div>\n                                </div>\n                                ).<p></p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>In early childhood to adolescence, <em><strong>Staphylococcus aureus</strong></em> is the dominant colonizing and infectious pathogen.&nbsp;</li>\n\t<li>By adulthood, <em><strong>Pseudomonas aeruginosa</strong></em> is the most common (~75% of patients are colonized), reflecting progression of bronchiectasis and biofilm formation.&nbsp;</li>\n</ul><br><br><p>With progressive disease, patients are also at risk for colonization with <em><strong>Burkholderia cepacia</strong></em> complex, a fastidious gram-negative bacterium that is often difficult to eradicate and associated with increased morbidity and mortality.</p>\n<h1>Clinical presentation</h1><br><br><p>Manifestations of CF reflect mucus clogging in various organs causing a direct and indirect effects (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L29331.jpg\" alt=\"figure 6\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 6</div>\n                                </div>\n                                ).<p></p>\n<h2>Constitutional</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Cachexia or failure to thrive (eg, slow childhood growth curves) due to chronic/recurrent respiratory infections and nutrient deficiencies (eg, fat malabsorption from exocrine pancreatic failure)</li>\n</ul>\n<h2>Sinopulmonary</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Sinuses:&nbsp; acute and chronic sinusitis; nasal polyps (hyperplastic)</li>\n\t<li>Airways:&nbsp; bronchiectasis (dilation, thick mucus, obstruction) with intermittent acute exacerbations (similar to pneumonia); allergic bronchopulmonary aspergillosis (ABPA) (\n                                <div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/65216.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 1\n                                    </a>\n                                </div>\n                                ) (eg, asthmatic wheezing, bronchiectasis with mucus plugs and brownish sputum, high IgE) due to fungal spore trapping and hypersensitivity</li>\n\t<li>Lung parenchyma:&nbsp; postinflammatory fibrosis (eg, from previous pneumonias and bronchiectasis exacerbations)</li>\n\t<li>Heart:&nbsp; secondary pulmonary hypertension (cor pulmonale); right ventricular failure; digital clubbing due to chronic mucopurulent lung disease</li>\n</ul>\n<h2>Gastrointestinal</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Pancreatic:&nbsp; acute and chronic pancreatitis (autodestruction by unreleased pancreatic enzymes), CF-related diabetes (endocrine insufficiency), fat and protein maldigestion and malabsorption (exocrine insufficiency) due to decreased secretion of proteases and lipases</li>\n\t<li>Luminal:&nbsp; meconium ileus (neonatal) and distal intestinal obstruction syndrome (adult equivalent), chronic constipation (often severe), large bowel obstruction, gut dysmotility, and bacterial overgrowth</li>\n\t<li>Hepatobiliary:&nbsp; gallbladder sludging, cholelithiasis and acute gallstone disease (eg, cholecystitis), cholestatic liver disease (can progress to cirrhosis), fat soluble vitamin (vitamins A, D, E, and K [ADEK]) deficiency (eg, coagulopathy)</li>\n</ul>\n<h2>Reproductive</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Obstructive azoospermia Â± congenital bilateral absence of vas deferens (~100% male infertility)</li>\n\t<li>Fallopian tube dysfunction (~20% female infertility)</li>\n</ul>\n<h2>Other</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Musculoskeletal:&nbsp; osteopenia, osteoporosis, and fractures (eg, vitamin D malabsorption)</li>\n\t<li>Cutaneous:&nbsp; severe aquagenic wrinkling (eg, palms and soles)</li>\n</ul>\n<h1>Diagnosis</h1><h2>Chest imaging</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Bronchiectasis:&nbsp; Chest x-ray is insufficient to visualize bronchiectasis but may show a generally \"dirty\" appearance with increased bronchial markings and hazy peribronchial fibrosis (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L69316.png\" alt=\"image 1\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">image 1</div>\n                                </div>\n                                ).&nbsp; CT (preferably high-resolution chest CT) more clearly shows the characteristic signs of bronchiectasis including airway wall thickening, dilation (bronchoarterial diameter ratio &gt;1, creating a \"<strong>signet ring</strong>\"), and lack of bronchial tapering (airways maintain their same caliber beyond the peripheral 1/3 of the lung) (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L87007.png\" alt=\"image 2\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">image 2</div>\n                                </div>\n                                ).&nbsp; The thickened walls with lack of tapering lead to cylindrical airway segments, appearing as parallel \"<strong>tram tracks</strong>\" when viewed in a radiographic plane (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L14011.png\" alt=\"image 3\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">image 3</div>\n                                </div>\n                                ).&nbsp; Copious mucus impaction (ie, secretions in dilated airways) is also commonly seen.&nbsp;</li>\n\t<li>Fibrosis:&nbsp; Patchy and nodular scarring are seen diffusely throughout the lungs but mostly in a bronchocentric distribution, due to repeated episodes of infection and inflammation.</li>\n\t<li>Bronchiectasis progresses from cylindrical (early) to cystic (end-stage), where the extensive dilation of the distal airways causes them to appear as cystic spaces, similar to a bunch of grapes (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L380.png\" alt=\"image 4\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">image 4</div>\n                                </div>\n                                ).&nbsp;</li>\n\t<li>The combination of <strong>cysts</strong> and <strong>fibrosis</strong> (also seen in the pancreas) gives CF its name.&nbsp;</li>\n</ul>\n<h2>Pulmonary function testing</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Although bronchiectatic airways are dilated, they are hypercollapsible (weakened walls).&nbsp; Expiratory collapse, combined with mucus impaction, leads to a predominantly <strong>obstructive pattern</strong> (ie, FEV<font size=\"2\"><sub>1</sub></font>/FVC &lt;0.7) on spirometry.&nbsp; With extensive fibrosis, a restrictive component can be seen as well.</li>\n</ul>\n<h2>Diagnostic approach</h2><br><br><p>Diagnosis of CF involves a combination of a positive clinical screen PLUS evidence of CFTR dysfunction (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/120020.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 2\n                                    </a>\n                                </div>\n                                ).<p></p><br><br><p>Today, newborn screening with confirmatory positive sweat chloride diagnoses the vast majority of cases.&nbsp; Occasionally, older patients (especially those with lower penetrance mutations causing slower disease progression) can be diagnosed retroactively based on clinical features and follow-up CFTR testing.&nbsp; CF is sometimes first evaluated during investigations for infertility.</p><br><br><p>Some patients with suspected CF have intermediate results (eg, &lt;2 major <em>CFTR</em> mutations, intermediate sweat chloride levels [30-59 mmol/L]).&nbsp; In these cases, more intensive workup is needed (expanded DNA analysis [whole-gene sequencing], nasal epithelial potential difference, fecal elastase measurement, semen analysis).</p>\n<h2>Universal newborn screening</h2><br><br><p>The inclusion of CF in newborn screening (NBS) along with other genetic conditions (eg, phenylketonuria, aminoacidurias) is now widespread (eg, all 50 states in the United States).&nbsp; Early detection of CF reduces mortality, slows lung disease progression, and improves growth and developmental outcomes.</p><br><br><p>NBS involves sequential testing using the following methods:</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Immunoreactive trypsinogen (IRT):&nbsp; IRT detects elevated levels of trypsinogen (a propeptide of trypsinogen) that accumulates in the blood due to defective pancreatic secretion.</li>\n\t<li>DNA mutation screen:&nbsp; DNA mutation screen is a PCR-based assay that detects the 40 most common <em>CFTR</em> mutations (accounting for ~85% of cases in Caucasians).&nbsp;</li>\n</ul><br><br><p>When NBS is positive, infants undergo confirmatory testing with a pilocarpine sweat chloride assay.</p><br><br><p>The incidence of CF remains stable (~1/3000 births) due to unchanging prevalence of mutant <em>CFTR</em> alleles.&nbsp; This is likely because <strong>carriers</strong> of <em>CFTR</em> mutation (ie, heterozygous) are asymptomatic and have normal fertility, and CFTR disease (ie, homozygous) is not embryonically lethal.&nbsp; The persistence of abnormal CFTR may have served an evolutionary purpose (eg, protection against chloride-wasting diarrheal illnesses such as cholera).</p>\n<h1>Differential diagnosis</h1><br><br><p>The differential diagnosis of CF can be considered based on the primary presentation:</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Bronchiectasis and recurrent pulmonary infections</li>\n\t<li>Obstructive lung disease and hepatic or pancreatic disease</li>\n\t<li>Delayed meconium passage</li>\n</ul><br><br><p>These are explored in more detail in the following sections.</p>\n<h1>Bronchiectasis and recurrent pulmonary infections</h1><br><br><p>CF causes bronchiectasis and frequent respiratory infections.&nbsp; However, several other conditions are on the differential.&nbsp; Similar to the framework for recurrent pneumonia (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/79693.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 3\n                                    </a>\n                                </div>\n                                ), they are conceptualized based on whether the bronchiectasis is diffuse or focal.<p></p>\n<h2>Diffuse bronchiectasis (bilateral, multiple lobes) </h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>Primary ciliary dyskinesia (PCD)</strong> (\n                                <div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/80965.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 4\n                                    </a>\n                                </div>\n                                ) is caused by mutations in dynein and kinesin (rotational motor proteins).&nbsp; Immotile cilia lead to mucostasis, bacterial overgrowth, and widespread bronchiectasis.&nbsp; Unlike CF, PCD is associated with additional features such as organ heterotaxy (eg, situs inversus, dextrocardia).&nbsp; Individuals with PCD typically have normal growth (versus failure to thrive in CF) and preserved gastrointestinal, nutritional, and pancreatic function.&nbsp; Finally, infertility in PCD is due to paralyzed spermatozoa (defective flagella) rather than obstruction or absence of the vas deferens in CF.</li>\n\t<li><strong>Primary immunodeficiency (eg, agammaglobulinemia)</strong> is caused by marked depletion of B lymphocytes and immunoglobulin levels (especially IgA, IgG, IgM) in humoral immunodeficiency (eg, Bruton X-linked) or combined immunodeficiency (eg, severe combined immune deficiency [SCID] or severe cases of common variable immune deficiency [CVID]).&nbsp; Recurrent pneumonia and dysregulated inflammation causes widespread bronchiectasis.&nbsp; Chronic diarrhea (rather than constipation in CF) is common and infections frequently occur in extrapulmonary sites (eg, skin and soft tissue abscesses) as well.</li>\n</ul>\n<h2>Focal bronchiectasis (unilateral, single lobe) </h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>Anatomic obstruction</strong> is caused by airway blockage by foreign body (eg, aspirated lego piece), extrinsic compression (eg, mediastinal lymphadenopathy), or intrinsic obstruction (eg, endobronchial lung cancer).&nbsp; Obstruction causes stagnation of mucus in the downstream lobe, leading to recurrent episodes of post-obstructive pneumonia, airway damage, and regional bronchiectasis.&nbsp; The offending lesion can often be seen on chest imaging or bronchoscopy.</li>\n\t<li><strong>Recurrent aspiration</strong> is caused by repeated aspiration pneumonia (gastric acid + oral flora), mainly in the setting of dysphagia (eg, dementia, stroke) or esophageal dysmotility.&nbsp; History is characterized by several distinct acute episodes of pneumonia (ie, several hospitalizations), mainly with infiltrates affecting the right lower lobe.</li>\n</ul>\n<h2>Other causes of bronchiectasis</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>Traction bronchiectasis</strong> (eg, fibrotic interstitial lung disease) (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L97519.jpg\" alt=\"figure 7\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 7</div>\n                                </div>\n                                ):&nbsp; Parenchymal fibrosis (eg, idiopathic pulmonary fibrosis) pulls the airways open as part of overall lung architectural distortion.&nbsp; In contrast to the mucopurulent (ie, thick, viscous secretions) bronchiectasis in CF, traction bronchiectasis is bland (ie, dry cough) and not associated with chronic bacterial (eg, <em>Pseudomonas</em>) colonization.&nbsp; Lung function is restricted (eg, volume loss in idiopathic pulmonary fibrosis) rather than obstructed (eg, hyperinflation in CF).</li>\n\t<li><strong>Nontuberculous mycobacterial (NTM) infection (eg,</strong> <em><strong>Mycobacterium avium</strong></em> <strong>complex):</strong>&nbsp; Chronic NTM infection is the most rapidly growing etiology of bronchiectasis in adults.&nbsp; Risk factors include immunodeficiencies (eg, chronic oral corticosteroid use) and certain body morphotypes (eg, thin elderly women, named \"Lady Windermere syndrome\" after an elderly female character in a play who would suppress her cough due to her Victorian manners).&nbsp; Like CF, constitutional symptoms (eg, cachexia) and chronic mucoid cough are common (but develop in adulthood).&nbsp; Unlike CF, sputum analysis shows acid fast bacilli (instead of <em>Pseudomonas</em> or <em>S aureus</em>) and extrapulmonary symptoms are not seen.&nbsp;</li>\n</ul>\n<h1>Obstructive lung disease and hepatic or pancreatic disease</h1><br><br><p>Alpha-1 antitrypsin (A1AT) deficiency can produce lung, liver, and pancreatic disease (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/42498.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 5\n                                    </a>\n                                </div>\n                                ).<p></p><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Like CF, pulmonary manifestations of A1AT deficiency include early onset obstructive lung disease in the absence of significant smoking exposure.&nbsp; However, the lung disease appears in middle adulthood (vs childhood in CF) and most commonly involves panacinar emphysema (versus bronchiectasis and fibrosis in CF); less commonly, chronic bronchitis and bronchiectasis can be seen with A1AT deficiency but generally involve sterile inflammation (vs chronic dense bacterial colonization in CF).&nbsp;</li>\n\t<li>Like CF, extrapulmonary manifestations of A1A deficiencyT include liver disease and recurrent attacks of acute pancreatitis (due to imbalance protease activity).&nbsp; However, the liver disease of A1AT involves a hepatocellular pattern (ie, â†‘ transaminases &gt; bilirubin and alkaline phosphatase) of injury, as opposed to a cholestatic pattern (ie, â†‘ bilirubin and alkaline phosphatase &gt; transaminases) in CF.&nbsp;</li>\n</ul>\n<h1>Infant with delayed meconium passage</h1><br><br><p>CF is the main cause of delayed meconium transit (ie, no passage within 48 hours after birth), leading to potential bowel obstruction in infants.&nbsp; However, other conditions are on the differential (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/120022.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 6\n                                    </a>\n                                </div>\n                                ).<p></p><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>Meconium plug syndrome</strong> is a relatively benign and self-limited condition in which large amounts of normal meconium cause colonic obstruction.&nbsp; It affects otherwise healthy neonates.&nbsp; The colonic transition point is typically located in the descending colon (proximal dilation, distal narrowing) versus the ileocecal junction in CF-related meconium ileus (pancolonic narrowing).&nbsp; The condition responds well to conservative management (eg, nasogastric decompression, osmotic enemas to evaluate meconium).</li>\n\t<li><strong>Hirschsprung disease</strong> represents congenital aganglionic megacolon (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L111727.jpg\" alt=\"figure 8\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 8</div>\n                                </div>\n                                ).&nbsp; Due to aperistalsis, the entire colon dilates, creating a transition point at the rectosigmoid junction (vs pancolonic narrowing in CF-related meconium ileus).&nbsp; Clinical clues include a narrowed rectum and tight internal anal sphincter (due to failure of anorectal inhibitory reflex) on digital examination.&nbsp; Diagnosis is made by suction biopsy demonstrating absence of myenteric ganglia.&nbsp;</li>\n</ul><br><br><p>All 3 conditions can result in high-grade bowel obstruction (eg, abdominal distension, bilious emesis).&nbsp; However, meconium plug syndrome and Hirschsprung disease produce dilation (megacolon) rather than narrowing (microcolon), and the meconium consistency is normal rather than inspissated.</p>\n<h1>Management of CF pulmonary disease</h1><h2>Stable disease</h2><br><br><p>Chronic management of CF bronchiectasis prioritizes mucus clearance and infection prevention in order to avoid further airway remodeling and subsequent loss of lung function.</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>Airway clearance techniques</strong> (ACT):&nbsp; Chest percussion (eg, manual hand clapping), huff coughing, high-frequency vibratory vest, and oscillating positive expiratory pressure (PEP) devices (eg, Acapellaâ„¢ flutter valve) are used to dislodge and mobilize thick bronchial mucus.</li>\n\t<li><strong>Mucolytic agents:</strong>&nbsp; Nebulized hypertonic saline (eg, 6%) and nuclease therapy (eg, inhaled DNAse) help to rehydrate mucus and decrease viscosity.</li>\n\t<li><strong>Antibiotics:</strong>&nbsp; Rotating inhaled antibiotics (eg, tobramycin, aztreonam) are given to decrease <em>Pseudomonas</em> burden.&nbsp; Prophylactic macrolide (eg, azithromycin) is also employed for its anti-inflammatory properties.</li>\n\t<li><strong>Bronchodilators:</strong>&nbsp; Beta agonists (eg, albuterol) can relieve inflammatory bronchospasm (eg, asthma overlap) and are often administered prior to other inhaled medications (to improve lung penetration).</li>\n\t<li><strong>Supportive measures:</strong>\n\t<ul class=\"article-body-unordered-list\">\n\t\t<li>Pulmonary rehabilitation (for all patients with functional limitation due to dyspnea)</li>\n\t\t<li>Immunization against respiratory pathogens (eg, respiratory syncytial virus [RSV], COVID, <em>Pneumococcus</em>, influenza)</li>\n\t\t<li>Supplemental oxygen (to maintain SpO<font size=\"2\"><sub>2</sub></font> &gt;92%)</li>\n\t\t<li>Noninvasive ventilatory support (for chronic hypercapnic respiratory failure)</li>\n\t</ul>\n\t</li>\n</ul><br><br><p>Pulmonary function must be monitored closely (ie, regular spirometry to measure FEV<font size=\"2\"><sub>1</sub></font> is recommended every 3 months).&nbsp; Patients can develop steep declines in FEV<font size=\"2\"><sub>1</sub></font>, heralding an acute bronchiectasis exacerbation, even though their daily symptom may be relatively stable.</p>\n<h2>Acute bronchiectasis exacerbations</h2><br><br><p>An acute bronchiectasis exacerbation (sometimes called a CF pulmonary exacerbation) is defined as an increase in symptoms (eg, worsening dyspnea, acute hemoptysis) and/or a significant decline in FEV<font size=\"2\"><sub>1</sub></font> (eg, â‰¥10% drop from baseline over several weeks).&nbsp; Exacerbations are typically triggered by new infection (mainly respiratory viruses) or increasing burden of existing bacterial colonizers.</p><br><br><p>Management usually involves hospital admission for <strong>intravenous broad spectrum antibiotics</strong> consisting of antistaphylococcal and double antipseudomonal coverage (eg, vancomycin + cefepime + amikacin).&nbsp; Sputum should be recultured to evaluate for emerging resistance.&nbsp; A short course of glucocorticoids (inhaled Â± systemic) is often administered to patients with a bronchoreactive (asthmatic) component.&nbsp; Other outpatient therapies (eg, ACT, mucolytics) are continued.</p><br><br><p>Bronchiectasis can erode into nearby bronchial arteries.&nbsp; New hemoptysis signals exacerbation (reflecting heightened inflammation) and often resolves with antibiotic treatment.&nbsp; Patients with life-threatening hemoptysis (eg, &gt;240 mL/24h or causing worsening hypoxemia) should be intubated for airway protection and treated with bronchial artery embolization; chest physiotherapy is generally suspended until the hemoptysis resolves.</p>\n<h1>Management of CF extrapulmonary disease</h1><br><br><p>Management of extrapulmonary CF mainly revolves around gastrointestinal and nutritional issues.</p>\n<h2>Endocrine pancreatic dysfunction (CF-related diabetes)</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Annual screening with oral glucose tolerance test (preferred over HbA1c due to higher sensitivity)&nbsp;</li>\n\t<li>Antidiabetic drugs (eg, ~40% require basal insulin by age 40)</li>\n</ul>\n<h2>Exocrine pancreatic dysfunction (maldigestion and malabsorption)</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>Pancreatic enzyme replacement therapy</strong>, involving a mixture of digestive proteases, lipases, and amylase to assist in protein, fat, and carbohydrate processing respectively</li>\n\t<li>Vitamin <strong>(ADEK)</strong> supplementation for all patients</li>\n\t<li>Enteral (eg, nasojejunal tube) or parenteral (ie, intravenous) feeding for severe malnutrition</li>\n</ul>\n<h2>Cholestatic liver disease</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Ursodeoxycholic acid (a choleretic agent) promotes bile acid flow and decreases biliary inflammation</li>\n</ul>\n<h2>Constipation</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Daily bowel regimen (eg, sennoside [motility stimulant] + polyethylene glycol [osmotic agent]) to prevent constipation</li>\n\t<li>Chloride channel agonist (eg, lubiprostone) for severe constipation</li>\n</ul>\n<h2>Osteoporosis</h2><br><br><ul class=\"article-body-unordered-list\">\n\t<li>Regular <strong>DEXA screening</strong> (~20% have osteoporotic compression fractures by age 20)</li>\n\t<li>Calcium and vitamin D supplementation, avoidance of systemic glucocorticoids, limited role for bisphosphonates</li>\n</ul>\n<h1>CFTR modulators&nbsp;</h1><br><br><p>In the last decade, several new drugs were commercialized that rescue aspects of CFTR function.&nbsp; They operate via 2 main mechanisms:</p><br><br><ul class=\"article-body-unordered-list\">\n\t<li><strong>Correctors</strong> (eg, lumacaftor, tezacaftor):&nbsp; These drugs restore proper folding and stabilization of CFTR, allowing successful trafficking to the cell surface.&nbsp; They are especially effective for mutations that result in CFTR misfolding and degradation (eg, Î”F508).</li>\n\t<li><strong>Potentiators</strong> (eg, ivacaftor):&nbsp; These drugs increase the opening probability of CFTR, allowing for more effective transport of chloride.&nbsp; They are especially effective for mutations that result in abnormal CFTR ion gating (eg, G551D).</li>\n</ul><br><br><p>The most common CFTR modulator regimen (elexacaftor-tezacaftor-ivacaftor) is a fixed-dose triple therapy that combines a potentiator and 2 correctors.&nbsp; CFTR modulators are recommended for any patient with a responsive mutation; therefore, CFTR genotyping is the standard of care for all patients.</p>\n<h1>Prognosis</h1><br><br><p>Survival in CF has steadily improved, with an unprecedented jump after the introduction of CFTR modulators (median survival increased from 40 in 2013 to 70 in 2023).&nbsp; In terms of pulmonary status, most patients have complete resolution of respiratory symptoms and normalization of lung function.&nbsp; In terms of extrapulmonary status, CFTR modulator therapy markedly improves virtually all aspects of organ dysfunction (eg, resolution of constipation, pancreatic insufficiency, and liver disease).&nbsp; Because of their transformative impact, CFTR modulators have been deemed an \"effective cure\" (for patients with eligible mutations).</p><br><br><p>Despite these advances, the burden on patients is considerable.&nbsp; For example, upon awakening, a typical teenager with CF must perform ACT (~30 minutes), followed by nebulized medications (~60 minutes), followed by oral and systemic medications (~30 minutes).&nbsp; This routine is then repeated again in the evening.&nbsp; Integrating these time-consuming (~5 hours/day) activities into school and daily life is taxing, requiring intensive support (eg, social work, mental health counseling) to help patients navigate their illness and to encourage adherence.</p><br><br><p>Some patients continue to suffer from progressive lung function decline with recurrent exacerbations.&nbsp; They eventually require bilateral lung transplantation (referred once FEV<font size=\"2\"><sub>1</sub></font> â‰¤35%).&nbsp; The most common cause of death in CF remains progressive respiratory failure, with gastrointestinal complications (eg, large bowel obstruction) a close second.</p>\n<h1>Summary</h1><br><br><p>Cystic fibrosis (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/38262.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">ðŸ“Š</span> View Table: table 7\n                                    </a>\n                                </div>\n                                ) is an autosomal recessive disorder resulting from mutations in the <em>CFTR</em> gene that impair chloride transport, leading to abnormally dehydrated mucus that obstructs and causes progressive dysfunction of multiple organs (eg, lungs, pancreas, gastrointestinal tract).&nbsp; Î”F508 is the most common mutation (~70% of cases) and causes misfolding and proteasomal degradation of CFTR.<p></p><br><br><p>Clinical manifestations include chronic and recurrent sinopulmonary infections, bronchiectasis, pancreatic insufficiency, and male infertility.&nbsp; Diagnosis requires the presence of a positive clinical criterion (eg, abnormal newborn screen) and proof of CFTR dysfunction (eg, elevated sweat chloride).&nbsp; Most cases are diagnosed based on universal newborn screening (eg, immunoreactive trypsinogen) with a confirmatory sweat chloride test.&nbsp; Management focuses on airway clearance techniques (eg, chest physiotherapy), mucolytic agents (eg, hypertonic saline), antibiotics (antipseudomonal), and CFTR modulators, which have dramatically improved survival rates and quality of life.&nbsp; Despite these advances, cystic fibrosis remains a lifelong condition requiring extensive daily treatments and multidisciplinary care.</p>\n</div>\n\n            "
}